• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

SEC launches probe, investors file suit against Mylan over EpiPen pricing

October 12, 2016 By Sarah Faulkner

SEC launches probe, investors file suit against Mylan Despite a $465 million settlement with the U.S. Justice Dept., Mylan (NSDQ:MYL) is still under fire for misclassifying its EpiPen auto-injector with the Centers for Medicare & Medicaid Services. Last week, the Securities & Exchange Commission’s enforcement division launched an investigation into the Canonsburg, Pa.-based company’s history with CMS; yesterday investors filed a purported class action seeking compensation for damages.

The lawsuit was filed in a New York district court, claiming that Mylan knowingly misled investors and issued false and misleading statements about the emergency allergy treatment. The group is seeking “compensation for all those who purchased or otherwise acquired Mylan N.V. ordinary shares and/or Mylan Inc. common stock” between February 2013 and October 2016.

The investors are questioning “whether defendants acted knowingly or recklessly in issuing false and misleading SEC filings and public statements during the class period; whether the prices of Mylan N.V. ordinary shares and the prices of Mylan Inc. common stock during the class period were artificially inflated because of the defendants’ conduct complained of herein; and whether the members of the class have sustained damages and, if so, what is the proper measure of damages,” according to court documents filed yesterday.

Mylan has been scrutinized by lawmakers over the last 2 months, including at a Congressional hearing in which CEO Heather Bresch maintained that Mylan is committed to making the lifesaving treatment available to any patient that needs it. The company is developing a generic that will be offered for $300, half the current price of the brand name product.

CMS reported last week that it spent $797 million on the EpiPen between 2011 and 2015, including rebates. In the DoJ settlement, Mylan said it will reclassify the EpiPen as a branded drug beginning in April 2017, which means the company will pay 23% in rebates instead of 13%.

“The terms of the settlement do not provide for any finding of wrongdoing on the part of Mylan Inc. or any of its affiliated entities or personnel,” the company wrote in a regulatory filing last week. “The settlement terms provide for resolution of all potential rebate liability claims by federal and state governments as to whether the product should have been classified as an innovator drug for CMS purposes, and subject to a higher rebate formula.”

Mylan’s shares dropped -10% to $42.64 apiece when criticism began to mount in August. The stock was trading at $38.22 per share in mid-morning activity today, down -0.2%.

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Legal News Tagged With: Mylan

IN CASE YOU MISSED IT

  • Medtronic to invest $50M in India Diabetes center
  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS